Key Highlights

  • Glucotrack completed its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed, Lōkahi-controlled healthcare platform.
  • Lōkahi securityholders received common and convertible preferred stock expected to yield approximately 90% fully diluted ownership of the combined company post-conversion.
  • Glucotrack's legacy continuous blood glucose monitoring (CBGM) business will operate as a separately capitalized, wholly owned subsidiary.
  • Erik Emerson has been appointed CEO of the combined company, while Paul Goode will serve as CTO of the parent and CEO of the CBGM subsidiary.

Glucotrack, Inc. (NASDAQ: GCTK) has completed its strategic business combination with Lōkahi Therapeutics, establishing a new publicly listed healthcare platform that will be controlled by Lōkahi following the transaction. The deal represents a significant restructuring of Glucotrack's corporate identity, transitioning the company from its historical focus on continuous blood glucose monitoring toward a broader, Lōkahi-led healthcare platform structure.

Under the terms of the transaction, Lōkahi securityholders received a combination of common and convertible preferred stock, an arrangement expected to yield approximately 90% fully diluted ownership of the combined company once the preferred shares convert. This ownership structure makes clear that Lōkahi is the controlling party in the newly combined entity, with legacy Glucotrack shareholders retaining a comparatively modest residual stake.

Importantly, Glucotrack's legacy continuous blood glucose monitoring (CBGM) business will not be wound down or abandoned as part of this transaction. Instead, it will continue operating as a separately capitalized, wholly owned subsidiary of the combined company, preserving the technology and business line while allowing it to be managed and funded distinctly from the broader parent organization's new strategic direction.

To support near-term operations following the combination, the deal is backed by a planned private placement financing, providing the newly formed entity with capital to fund its operations as it integrates the two businesses and establishes its go-forward strategic priorities under Lōkahi's control.

Leadership of the combined company reflects this new structure: Erik Emerson has been appointed Chief Executive Officer of the combined company, overseeing the broader Lōkahi-controlled healthcare platform. Meanwhile, Paul Goode will serve in a dual capacity as Chief Technical Officer of the parent company and as CEO of the specialized CBGM subsidiary, a structure designed to maintain dedicated leadership focus on the legacy glucose monitoring technology even as it operates within the larger combined entity.

For investors, this transaction represents a fundamental transformation of what Glucotrack represents as a public company, shifting from a pure-play continuous blood glucose monitoring developer to a broader, Lōkahi-controlled healthcare platform with the CBGM technology preserved as a distinct, separately capitalized subsidiary business line going forward.